Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation

CD49a Expression Defines Tissue-Resident CD8 + T Cells Poised for Cytotoxic Function in Human Skin

(2017) Stanley Cheuk et al.   IMMUNITY

Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations

(2017) Giovanna Tabellini et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation

(2017) Katja G. Weinacht et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

(2017) Ofer Zimmerman et al.   Open Forum Infectious Diseases

T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients

(2016) Zuzana Parackova et al.   AUTOIMMUNITY

Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype

(2016) J. Toubiana et al.   BLOOD

Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation

(2016) Rotraut Mössner et al.   CLINICAL INFECTIOUS DISEASES

Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1

(2016) Safa Baris et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)

(2015) Jie Zheng et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis

(2015) Frank L. van de Veerdonk et al.   IMMUNOLOGY LETTERS

Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation

(2015) Eleanor Higgins et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies

(2015) Cindy S. Ma et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

(2015) Mignon L. Loh et al.   PEDIATRIC BLOOD & CANCER

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

A Negative Feedback Loop Mediated by STAT3 Limits Human Th17 Responses

(2014) H. A. Purvis et al.   JOURNAL OF IMMUNOLOGY

The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders

(2013) Yasuko Furumoto et al.   BIODRUGS

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome

(2013) Gulbu Uzel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival

(2013) Neil Romberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Fatal combined immunodeficiency associated with heterozygous mutation in STAT1

(2013) Nigel Sharfe et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Human Natural Killer Cells Acting as Phagocytes Against Candida albicans and Mounting an Inflammatory Response That Modulates Neutrophil Antifungal Activity

(2013) Jessica Voigt et al.   JOURNAL OF INFECTIOUS DISEASES

New and recurrent gain-of-functionSTAT1mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe

(2013) Beáta Soltész et al.   JOURNAL OF MEDICAL GENETICS

Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis

(2012) Anne Puel et al.   Current Opinion in Allergy and Clinical Immunology

Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes

(2012) Stephanie Boisson-Dupuis et al.   CURRENT OPINION IN IMMUNOLOGY

Inborn Errors of Human JAKs and STATs

(2012) Jean-Laurent Casanova et al.   IMMUNITY

Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species

(2012) László Maródi et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms

(2012) Ayalew Tefferi   NEW ENGLAND JOURNAL OF MEDICINE

Type I interferonopathies: a novel set of inborn errors of immunity

(2011) Yanick J. Crow   Annals of the New York Academy of Sciences

Growth hormone-STAT5 regulation of growth, hepatocellular carcinoma, and liver metabolism

(2011) Myunggi Baik et al.   Annals of the New York Academy of Sciences

Gain-of-function humanSTAT1mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis

(2011) Luyan Liu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

(2011) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

The Influence of Excessive IL-6 Production In Vivo on the Development and Function of Foxp3+ Regulatory T Cells

(2010) M. Fujimoto et al.   JOURNAL OF IMMUNOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

V 1 T lymphocytes producing IFN-  and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans

(2009) D. Fenoglio et al.   BLOOD

A phosphorylation-acetylation switch regulates STAT1 signaling

(2009) O. H. Kramer et al.   GENES & DEVELOPMENT

IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells

(2008) T. Korn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA